 "Swiss firm Datwyler to expand sealing facility in Maharashtra")
Datwyler - the Switzerland-based global supplier of customised sealing solutions to manufacturers and companies which operate in the healthcare, automotive, civil engineering and consumer goods sectors – will construct its most advanced manufacturing facility - FirstLine - at the Datwyler India’s Satara site in Maharashtra. The FirstLine facility, to be integrated in the existing premise, will be fully operational in 2017. The most complex rubber components produced at the FirstLine site belong to the Omniflex family of vial and syringe components, which prevent any interaction with the drugs due to their total fluoropolymer coating. These components are exclusively manufactured at the FirstLine sites.
Omniflex, a Datwyler proprietary process, is an inert, flexible, fluorinated polymer coating for pharmaceutical rubber closures, which covers the entire product surface. The chemical inertness of the fluorinated polymer coating provides a very high degree of compatibility with pharmaceutical or biotechnology products. Datwyler India will supply the products made in the FirstLine production facility in Satara to the company’s customers worldwide.
Rahul Dev, vice president, Datwyler India, said, “Datwyler’s latest investment in India through the commencement of the FirstLine facility in Satara is part of the company’s commitment to India and the Asian markets. Present in India since 2010, Datwyler is dedicated to guaranteeing the highest levels of quality and safety, and continues to make investments aimed at meeting global regulatory requirements. The plant currently employs 290 people. It will employ 350 people by the time the production starts in 2017.”
India’s pharmaceutical and biotech markets are evolving rapidly and have been able to gain traction from global manufacturers, suppliers and customers. The country is also getting recognised as one of the global manufacturing destinations. “Our new FirstLine facility in Satara makes a great business case for us as we look at catering to global markets. Datwyler is one of the leading producers of closure solutions for injectable and vial medicines. The company’s products are supplied to the world’s leading pharmaceutical and biotechnology companies to support their efforts towards save and effective drug delivery for a healthier world,” added Dev.
ALSO READ: Italy's IMA to enhance packaging machinery exports from Hassia India
The healthcare unit of the Datwyler Sealing Solutions division designs, develops and manufactures solutions for injectable packaging and drug delivery systems to facilitate customers to create a safer medical environment. In addition to the Omniflex series, vial stoppers of different sizes as well as plunger stoppers will be produced in this FirstLine facility.
The Datwyler Group offers a range of specialised and unique coatings, elastomer formulations, and aluminium seals that allow customers to effectively package and administer drug products in the most efficient manner. Datwyler’s products are supplied to the world’s leading pharmaceutical and biotechnology companies to support their efforts towards safe and effective drug delivery for a healthier world. With a global manufacturing footprint on three continents and sales in over 100 countries, the Datwyler Sealing Solutions division generates an annual revenue in excess of Euro 500 million.
Omniflex, a Datwyler proprietary process, is an inert, flexible, fluorinated polymer coating for pharmaceutical rubber closures, which covers the entire product surface. The chemical inertness of the fluorinated polymer coating provides a very high degree of compatibility with pharmaceutical or biotechnology products. Datwyler India will supply the products made in the FirstLine production facility in Satara to the company’s customers worldwide.
Rahul Dev, vice president, Datwyler India, said, “Datwyler’s latest investment in India through the commencement of the FirstLine facility in Satara is part of the company’s commitment to India and the Asian markets. Present in India since 2010, Datwyler is dedicated to guaranteeing the highest levels of quality and safety, and continues to make investments aimed at meeting global regulatory requirements. The plant currently employs 290 people. It will employ 350 people by the time the production starts in 2017.”
India’s pharmaceutical and biotech markets are evolving rapidly and have been able to gain traction from global manufacturers, suppliers and customers. The country is also getting recognised as one of the global manufacturing destinations. “Our new FirstLine facility in Satara makes a great business case for us as we look at catering to global markets. Datwyler is one of the leading producers of closure solutions for injectable and vial medicines. The company’s products are supplied to the world’s leading pharmaceutical and biotechnology companies to support their efforts towards save and effective drug delivery for a healthier world,” added Dev.
ALSO READ: Italy's IMA to enhance packaging machinery exports from Hassia India
The healthcare unit of the Datwyler Sealing Solutions division designs, develops and manufactures solutions for injectable packaging and drug delivery systems to facilitate customers to create a safer medical environment. In addition to the Omniflex series, vial stoppers of different sizes as well as plunger stoppers will be produced in this FirstLine facility.
The Datwyler Group offers a range of specialised and unique coatings, elastomer formulations, and aluminium seals that allow customers to effectively package and administer drug products in the most efficient manner. Datwyler’s products are supplied to the world’s leading pharmaceutical and biotechnology companies to support their efforts towards safe and effective drug delivery for a healthier world. With a global manufacturing footprint on three continents and sales in over 100 countries, the Datwyler Sealing Solutions division generates an annual revenue in excess of Euro 500 million.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%